The vaccine developed by Pfizer Inc. of the United States and Biotech SE of Germany to control the coronavirus virus code 19 succeeded in preventing more than 90% of the infections in thousands of volunteers.
This is by far the most encouraging scientific development in the fight against the corona virus epidemic.
Preliminary results of the vaccine were released by the companies so that they could approach the authorities for approval of emergency use after further investigation confirms its safety.
Read More:Cough can carry the corona virus more than 6 feet, research says
“This is a great day for public health because we have found a way out of the situation we are currently in,” said Bill Gruber, a leading scientist who developed the Phaser vaccine.
The findings are based on a preliminary analysis of nearly 44,000 people in the United States and five other countries, and 94 volunteers from two groups who received placebo and vaccines.
The company did not provide further details on the cases, how many people were vaccinated, but said the initial immunization rate could change by the end of the study.
However, the efficacy of more than 90% indicates that barely 8 out of 94 vaccinators will be infected with code 19.
The vaccine is given in the form of 2 doses in 21 days, while the US Food and Drug Administration has set an effective rate of just over 50% for the approval of a corona virus.
The trial will be continued by the company to confirm the effectiveness of the vaccine until the number of code 19 cases among volunteers reaches 164.
Bill Gruber said that given the increase in the number of Code 19 cases in the United States, it is estimated that 164 cases could be reported in early December.
This is the first time that pharmaceutical companies have released data on the success of a large-scale trial of a corona virus vaccine.
The companies say no harm has been detected so far and may approach the US administration this month for approval of emergency use of the vaccine.
If this is allowed, the dose of the vaccine will be limited initially and other questions such as how long the vaccine will provide protection will not be answered.
But it certainly raises the expectation that other Code 19 vaccines currently undergoing development may be effective.
Read More:Have researchers discovered a cheaper alternative to the corona vaccine?
“Today is a great day for science and humanity. We are reaching the most important milestone in vaccine development at a time when the world needs it most, because of the high rate of cases,” said Albert Borla, Pfizer’s chairman and chief executive. There has been a record increase in capacity and hospitals are running out of capacity.
The company will ask the US administration to approve the vaccine for emergency use in people between the ages of 16 and 85.
To that end, it will need 2 months of safety data from 50 percent of the 44,000 people surveyed, expected by the end of this month.
Pfizer and Biotech have agreed to provide 100 million vaccine doses to the US government for امریکی 1.9 billion, while similar agreements have been reached with the European Union, the United Kingdom, Canada and Japan.
To save time, the companies started producing the vaccine before they knew it was safe. They now expect to produce 50 million doses this year, meaning that 25 million people will be protected from the disease. Will be able
According to Pfizer, she expects to produce 1.3 billion doses of the vaccine by 2021.
Preliminary data have not yet been published in any reputable medical journal, and the company says the results will be released to a medical journal only after a full trial.
Several companies around the world are working to develop vaccines to prevent code 19.
Read More:The Oxford University corona vaccine is expected to be ready next month
The Phaser and Biotech vaccines use Messenger RNA (MRNA) technology, which relies on laboratory-generated genes.
This technology is designed to stimulate the immune response against disease without the use of real viral particles such as germs.
A similar technology is being used in the vaccine of another US company, Modrina, the results of the third phase of the trial are expected by the end of this month.